Skip to main content
SpringerLink
Log in

Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology

  • Book
  • © 2016

Overview

Authors:
  1. Witold Lasek

    1. Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland

    View author publications

    You can also search for this author in PubMed   Google Scholar

  2. Radoslaw Zagozdzon

    1. Department of Immunology, Medical University of Warsaw, Warsaw, Poland

    View author publications

    You can also search for this author in PubMed   Google Scholar

  • Explores the biology of interleukin 12 and its potential in cancer therapy
  • Discusses antitumor effects identified in preclinical studies and clinical trials in cancer immunotherapy
  • Is particularly relevant for scientists working in the pharmaceutical industry and in clinical oncology
  • Includes supplementary material: sn.pub/extras

Part of the book series: SpringerBriefs in Immunology (BRIEFSIMMUN)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (3 chapters)

  1. Front Matter

    Pages i-vii
    Download chapter PDF

  2. Biology of IL-12

    • Radoslaw Zagozdzon, Witold Lasek
    Pages 1-19

  3. Antitumor Effects of IL-12 in Preclinical Studies

    • Witold Lasek, Marek Jakóbisiak
    Pages 21-41

  4. Clinical Trials with IL-12 in Cancer Immunotherapy

    • Witold Lasek, Radoslaw Zagozdzon
    Pages 43-75
Back to top

Keywords

About this book

This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).

Authors and Affiliations

  • Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland

    Witold Lasek

  • Department of Immunology, Medical University of Warsaw, Warsaw, Poland

    Radoslaw Zagozdzon

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation